Stock fact sheet · data as of
XBiotech Inc. (XBIT): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is XBIT undervalued?
At 2.16 (close of 16 Oct 2026), XBIT trades 47% below the GLS average fair value of 4.08. That average comes from 1 models run on the latest filings, and 1 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns XBiotech Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files XBIT under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for XBIT
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 4.08 | +89% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 3.84 | +78% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
XBiotech Inc. scores only 1 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -32.4%, ROE -32.4%, ROA -30.3% - with debt at 0.00 times equity and negative free cash flow.
XBiotech Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Manufacturing Revenue 100% (quarter Q4 FY2022).
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 1 / 9 | ROIC | -32.4% |
|---|---|---|---|
| GLS Moat | 1.7 / 10 | ROE | -32.4% |
| Debt / equity | 0.00 | ROA | -30.3% |
| Free-cash-flow yield | -62.0% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 36: Weak
With a Wheel Score of 36 XBiotech Inc. sits in the Weak band. The parts - Value 25/25, Health 2/20, Moat 3/15, Premium 0/20, Stability 6/20 - show where: Premium (0/20) scores lowest.
No implied volatility is recorded for XBIT - the nightly snapshot found no near-the-money contracts 20-60 days out - so the Premium part of the Wheel Score is zero. Chain open interest is thin - 239 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 66k shares a day on a market cap of $66M, with a beta of 0.80 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 47% margin of safety | |
| Health | 2 / 20 | Piotroski 1/9 | |
| Moat | 3 / 15 | moat 1.7/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 66k shares/day, $66M cap, beta 0.80 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for XBIT in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to XBiotech Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc. | 3.83 | - | - | 40Weak | $66M |
| HYFT MindWalk Holdings Corp. | 1.40 | - | - | 34Weak | $66M |
| OSTX OS Therapies Incorporated | 1.41 | - | - | 26No options | $66M |
| PMVP PMV Pharmaceuticals, Inc. | 1.24 | 0.6530 | -90% | 18Weak | $66M |
| SPRO Spero Therapeutics, Inc. | 1.12 | 3.81 | +71% | 56Fair | $65M |
| CSBR Champions Oncology, Inc. | 4.79 | 3.89 | -23% | 24Weak | $67M |
| TLSA Tiziana Life Sciences Ltd | 1.05 | 0.0186 | -5553% | 20Weak | $67M |
| CING Cingulate Inc. | 4.39 | 0.0505 | -8592% | 24Weak | $64M |
| FBIO Fortress Biotech, Inc. | 1.91 | 74.01 | +97% | 54Fair | $64M |
| MAIA MAIA Biotechnology, Inc. | 1.12 | 269.53 | +100% | 39No options | $69M |
| CGTX Cognition Therapeutics, Inc. | 0.7326 | 0.6038 | -21% | 17No options | $70M |
| AURX Nuo Therapeutics, Inc. | 1.28 | - | - | 25No options | $62M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about XBIT
Is XBIT undervalued right now?
By the GLS models, yes: at 2.16 the stock is 47% below the average fair value of 4.08 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of XBIT and what does it mean?
XBIT scores 36 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for XBIT?
4.08 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does XBiotech Inc. report earnings next?
No upcoming earnings date is recorded for XBIT in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does XBIT have listed options, and how liquid are they?
Yes. The nightly snapshot found 30 listed contracts with 239 open interest across all expiries. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.